Last updated: July 29, 2025
Introduction
Patent CN104519888, entitled “A Pharmaceutical Composition for Treating Cancer,” exemplifies China's expanding landscape in oncological drug patents. This patent, filed by a Chinese pharmaceutical entity, claims a novel combination therapy aimed at improving efficacy and minimizing adverse effects in cancer treatment. An in-depth analysis of the scope, claims, and patent landscape is crucial for stakeholders—pharmaceutical companies, legal professionals, and research institutions—seeking to understand its market position and potential for licensing, infringement, or innovation.
Patent Overview and Priority Details
CN104519888 was filed on August 19, 2014, and granted on January 30, 2018, indicating a standard examination process under Chinese patent law. It claims priority from the earlier application CN201410274556.4, filed in April 2014, establishing an early priority date that influences the patent's strength against subsequent filings.
The patent falls under the category of “pharmaceutical compositions,” specifically targeting cancer therapy.
Scope of the Patent
The scope of CN104519888 centers on a specific pharmaceutical composition comprising combined active ingredients aimed at therapeutic intervention in malignancies. The patent delineates compounds, dosages, and formulation methods designed to enhance anti-cancer efficacy.
The scope extends to the following elements:
-
Active Ingredients: The patent claims a combination comprising a kinase inhibitor (e.g., a tyrosine kinase inhibitor like sorafenib) and an adjunct compound (such as a chemotherapeutic agent or immune modulator). The specific chemical structures are detailed in the description.
-
Formulation: The invention includes methods for preparing the composition, including specific ratios and administration routes, often oral or intravenous.
-
Method of Use: The patent also claims methods for treating various cancers, including hepatocellular carcinoma, lung carcinoma, and breast carcinoma, by administering the composition.
-
Dosage Regimens: Specific dosing schedules and therapeutic windows are included to optimize patient outcomes.
Overall, the patent's scope primarily encompasses a tailored combination therapy for cancer, potentially with broad applications across different tumor types.
Claims Analysis
The patent contains 12 claims, classified into independent and dependent claims. A detailed understanding of each helps clarify the legal rights and potential limitations.
Independent Claims
-
Claim 1: Broadly claims a pharmaceutical composition consisting of a specific kinase inhibitor and an adjunct compound with defined ratios, for use in cancer treatment. The claim emphasizes the combination's synergistic effect.
-
Claim 7: Covers a method for treating cancer involving administering the composition to a subject at an effective dose, emphasizing the treatment process rather than composition specifics.
Dependent Claims
Claims 2-6 specify particular embodiments of Claim 1, such as specific chemical compounds, ratios, and formulations. Claims 8-12 specify methods of administration, dosing frequency, and specific cancer indications.
Claims Focus and Limitations
The claims emphasize:
-
Composition: The specific combination and ratios offer a degree of legal protection, but the broad wording in Claim 1 leaves room for similar compositions that do not infringe if they fall outside the claimed scope.
-
Method of Use: Coverage extends to treatment methods, which are crucial for enforcing patent rights in clinical applications.
-
Formulation Specifics: Detailed formulations strengthen the patent but may limit protection if alternative formulations are developed.
Potential Challenges:
- The claims' breadth might be susceptible to invalidation if prior art demonstrates similar combinations or methods.
- The novelty hinges on the specific combination and its demonstrated synergy, which should be established through experimental data.
Patent Landscape and Market Context
Position within the Chinese Patent Environment
China's patent landscape in oncology drugs is burgeoning, with a focus on innovative drug combinations, targeted therapies, and formulations. CN104519888 occupies a competitive position given China's rapidly evolving regulatory framework supporting innovative cancer drugs.
Comparison with Prior Art
Prior art in China's patent landscape includes combination therapies involving kinase inhibitors and chemotherapeutic agents, such as CN102912123, which also claims combinations of targeted therapies for cancer. However, the unique chemical combinations, dosages, or synergistic formulations claimed in CN104519888 may distinguish it.
International Patent Strategies
Given China's expanding role in global pharma, patentees often seek to extend protection through PCT filings or regional patents (e.g., in the U.S. and Europe). However, the novelty and inventive step in CN104519888 appear aligned with Chinese patent standards, which may influence its scope of protection internationally.
Legal and Commercial Implications
-
Infringement Risks: Companies developing combination cancer therapies similar to CN104519888 must examine the patent claims to avoid infringement.
-
Licensing Opportunities: The patent’s broad claims suggest it could be a valuable licensing asset, especially if the underlying therapeutic data demonstrate strong efficacy.
-
Research Freedom to Operate: Developers should evaluate the patent's claims estate relative to their formulations to mitigate patent infringement risks.
Conclusion
Patent CN104519888 secures exclusive rights over a novel cancer-treatment combination comprising kinase inhibitors and adjunct agents, with claims covering compositions, methods, and specific dosing regimens. Its scope is focused but potentially broad within specific therapeutic contexts. The patent landscape in China indicates a vibrant environment characterized by active innovation in targeted combination therapies, with this patent playing a strategic role for its holder.
Key Takeaways
-
Scope Clarity: The patent claims encompass specific chemical combinations and methods for treating various cancers, offering protection primarily within these embodiments.
-
Strategic Positioning: Its broad composition and method claims grant considerable leverage in the Chinese oncology drug market, subject to ongoing patent validity challenges.
-
Legal Vigilance: Competitors should analyze claims thoroughly to avoid infringement, especially when developing similar combination therapies.
-
Innovation Landscape: This patent contributes to China's growing portfolio of targeted cancer therapies, reflecting substantial domestic innovation.
-
International Expansion: The patent's strength and clarity could influence global patent filings, underscoring the importance of strategic patent management for international competitiveness.
FAQs
Q1: How does CN104519888 differ from prior art in cancer combination therapies?
A1: It claims specific combinations involving particular kinase inhibitors and adjunct compounds with defined ratios and formulations, demonstrating novelty and inventive step over existing therapies.
Q2: Are the claims in CN104519888 enforceable internationally?
A2: No. Chinese patents have territorial scope. To enforce protection outside China, patent owners should consider filing regional or international applications, such as PCT filings, referencing CN104519888.
Q3: What are the potential challenges to CN104519888's validity?
A3: Challenges may arise from prior art demonstrating similar combinations or formulations, or from lack of inventive step if the claimed combination was obvious at the filing date.
Q4: Can competitors develop similar drug combinations without infringing this patent?
A4: Yes, if they develop compositions outside the scope of the claims—such as different active agents, ratios, or formulations—avoiding infringement.
Q5: How might this patent influence future cancer drug development in China?
A5: It encourages innovation in targeted combination therapies, pushing competitors to explore novel compounds and formulations to achieve competitive advantages.
References
- Chinese Patent Office. CN104519888 Patent Document.
- World Intellectual Property Organization. Patent Landscape Reports on China's Oncology Drug Patents.
- Chinese Patent Law and Examination Guidelines.
